Vaxart, Inc. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables
Vaxart, Inc. (VXRT) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables of $14.67 million as of 2018-12-31, per its 10-K filed 2021-02-25.
Discontinued › Notes › Business Combinations › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) › Business Combination, Recognized Asset Acquired, Asset › Business Combination, Recognized Asset Acquired, Asset, Current
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables · last filed 2021-02-25
- 2018-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables $14.67M.
- 2018-09-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables $14.67M.
- 2018-06-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables $14.67M.
- 2018-02-13: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables $14.67M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables |
|---|---|
| 2018-12-31 | $14.67M 10-K · filed 2021-02-25 |
| 2018-09-30 | $14.67M 10-Q · filed 2018-11-13 |
| 2018-06-30 | $14.67M 10-Q · filed 2018-08-10 |
| 2018-02-13 | $14.67M 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |